Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cybin ( (TSE:CYBN) ) has issued an update.
Cybin Inc. will transfer its U.S. stock market listing from NYSE American to the Nasdaq Global Market, with trading on NYSE American ending on January 2, 2026 and Nasdaq trading beginning January 5, 2026. Concurrent with the move, the company will adopt the business name Helus Pharma and change its ticker symbol to “HELP” on both Nasdaq and Cboe Canada, a rebranding that management frames as a key step in its evolution and alignment with a larger peer group of global pharmaceutical companies, potentially enhancing its visibility with investors and its positioning within the mental health therapeutics sector.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$55.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin is a clinical-stage pharmaceutical company focused on transforming mental healthcare through next-generation psychedelic-based treatments for major depressive disorder, generalized anxiety disorder and other mental health conditions. Founded in 2019 and operating across Canada, the U.S., the U.K. and Ireland, the company is advancing lead candidates CYB003, now in Phase 3 trials with Breakthrough Therapy Designation from the U.S. FDA for adjunctive treatment of major depressive disorder, and CYB004, in a Phase 2 study for generalized anxiety disorder, alongside a broader pipeline of investigational compounds.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.92M
For a thorough assessment of CYBN stock, go to TipRanks’ Stock Analysis page.